DHL Group is significantly enhancing its Life Sciences and Healthcare capabilities in Singapore with a series of strategic investments aimed at reinforcing the nation’s status as Asia Pacific’s premier life sciences hub. This initiative includes the development of new and expanded facilities such as the upcoming Pharma Hub 2, the Singapore Coldchain Hub, and a GDP-compliant healthcare space at DHL Express South Asia Hub.
The investments are designed to cater to the growing demand for temperature-sensitive and high-value healthcare supply chains. Asia Pacific’s pharmaceutical logistics market is projected to grow from US$163b in 2025 to nearly US$239b by 2031, driven by the rising demand for biologics and vaccines. DHL’s new infrastructure will support the transport, storage, and distribution of pharmaceuticals, medical devices, and clinical trial materials across the region.
DHL Global Forwarding’s Singapore Coldchain Hub, located at Changi Nexus One, will provide 3,047 square metres of GDP-aligned, temperature-controlled infrastructure. This facility is set to launch in late 2027 and will ensure an unbroken cold chain for healthcare cargo, minimising temperature excursions and preserving product integrity.
Additionally, DHL Supply Chain is expanding its footprint with a second pharma hub, offering 8,000 square metres of controlled ambient storage. This facility will accommodate approximately 7,680 pallet positions and is expected to begin operations by the first half of 2027.
DHL is also investing in specialised healthcare logistics expertise, ensuring that temperature-sensitive products are handled consistently. The company is collaborating with partners like Life Science Incubator to support emerging healthcare businesses, aiming to strengthen the broader healthcare logistics ecosystem.
